Mondor疾病的特征是在特定解剖部位发生的急性疼痛性血栓性静脉炎。关于其发病率的数据,临床表现的特点,和课程是不可用的日期。我们研究了2004年至2020年在苏黎世(瑞士)大学医院诊断和随访的患者的Mondor病程。主要研究结果是在临床诊断Mondor疾病时或在1年内诊断出活动性癌症,以及1年全因死亡和复发性Mondor病。我们纳入了45例患者,并将他们分为三个Mondor疾病亚组之一:胸部(n=26),阴茎(n=12),或腋窝(n=7)。中位年龄为39岁(Q1-Q3:30-45岁),44%的患者为男性。在53.8%的胸廓型患者中,手术是引起Mondor病的可能原因,有阴茎位置的人中有41.7%,以及所有有腋窝位置的人。已知的活动性癌症在基线时存在于45名患者中的9名(20%)中。对43例患者进行了一年的随访(中位数为94个月),而其余2例患者的6个月数据可用.在可用的后续行动中,没有患者有新的癌症诊断。总之,五分之一的Mondor病患者在诊断时已知癌症。随访期间,新的癌症诊断率和死亡率可以忽略不计,为这种情况的良好预后提供保证。根据这些初步数据,对于Mondor病患者,除了目前指南推荐的普通人群外,可能不需要延长癌症筛查.
Mondor disease is characterized by an acute painful thrombophlebitis occurring at specific anatomical sites. Data on its incidence, characteristics of clinical presentation, and course are unavailable to date. We studied the course of Mondor disease in patients diagnosed and followed at the University Hospital Zurich (Switzerland) between 2004 and 2020. The primary
study outcomes were a diagnosis of active cancer either at the time of clinical diagnosis of Mondor disease or within 1 year, as well as 1-year all-cause death and recurrent Mondor disease. We included 45 patients and classified them into one of the three Mondor disease subgroups: thoracic (n = 26), penile (n = 12), or axillary (n = 7). The median age was 39 (Q1-Q3: 30-45) years and 44% of patients were men. Surgery was the likely cause of Mondor disease in 53.8% of patients with a thoracic form, 41.7% of those with a penile location, and all of those with an axillary location. Known active cancer was present in nine (20%) of 45 patients at baseline. One-year follow-up was available for 43 patients (median 94 months), whereas 6-month data were available for the remaining two patients. During the available follow-up, no patient had a new diagnosis of cancer. In conclusion, one in five patients with Mondor disease had known cancer at the time of diagnosis. During follow-up, the rate of new cancer diagnosis and death was negligible, providing reassurance about the good prognosis of this condition. Based on these preliminary data, extended cancer screening besides what is recommended by current guidelines for the general population might not be necessary in patients with Mondor disease.